- Home
- GROW vs XLO Comparison
GROW vs XLO Comparison
Compare GROW & XLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GROW | XLO |
|---|---|---|
| Founded | 1968 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 32.2M | 41.8M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | GROW | XLO |
|---|---|---|
| Price | $2.47 | $0.66 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $2.00 |
| AVG Volume (30 Days) | 32.6K | ★ 510.6K |
| Earning Date | 02-11-2026 | 11-13-2025 |
| Dividend Yield | ★ 3.72% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.07 | N/A |
| Revenue | $8,546,000.00 | ★ $31,804,000.00 |
| Revenue This Year | N/A | $626.78 |
| Revenue Next Year | N/A | $79.08 |
| P/E Ratio | $37.04 | ★ N/A |
| Revenue Growth | N/A | ★ 588.40 |
| 52 Week Low | $2.02 | $0.62 |
| 52 Week High | $2.78 | $1.70 |
Technical Indicators
Market Signals| Indicator | GROW | XLO |
|---|---|---|
| Relative Strength Index (RSI) | 55.06 | 39.03 |
| Support Level | $2.36 | $0.65 |
| Resistance Level | $2.45 | $0.68 |
| Average True Range (ATR) | 0.07 | 0.03 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 85.31 | 31.73 |
Price Performance
Historical ComparisonAbout GROW U.S. Global Investors Inc.
US Global Investors Inc is a registered investment advisory firm. The company manages the following business segments: Investment management services; through which the company offers, to U.S. Global Investors Funds (USGIF or the Funds) and exchange-traded fund (ETF) clients, a range of investment management products and services to meet the needs of individual and institutional investors; and Corporate Investments, through which the company invests for its own account in an effort to add growth and value to its cash position. It derives all its revenue from Investment management services.
About XLO Xilio Therapeutics Inc.
Xilio Therapeutics Inc is a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is using its proprietary platform to advance a pipeline of novel, tumor-activated clinical and preclinical I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment, including tumor-activated cytokines and antibodies and immune cell engagers.